Compare DexCom, Inc. (DXCM) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Gap Inc — how do they compare? DexCom, Inc. trades at $77.92 (market cap $28.06B), while Gap Inc trades at $20.53 (market cap $7.30B). The key difference: DexCom, Inc. is far larger — about 3.8× Gap Inc's market cap, and Gap Inc pays a 3.45% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | GAP | |
|---|---|---|
Market Cap | $28.06B | $7.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $29.13 |
52-Week Low | $54.84 | $18.35 |
Enterprise Value | $27.03B | $10.38B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Gap Inc. (GAP) trades at $20.65, up 2.58% today, with a bullish technical signal supported by oscillators and key resistance at $21. The stock shows strong fundamentals with a P/E of 8.05, net income margin of 6.25%, and consistent earnings beats in recent quarters. Revenue grew to $15.09B in 2025, and operating cash flow remains robust at $1.49B. Recent news highlights digital transformation efforts and a potential turnaround in the Athleta segment.
The outlook is positive with a consensus price target of $27.00, implying 30.7% upside, though risks include ongoing legal investigations and competitive pressures. Analyst sentiment is mixed with 39.58% buy ratings, but improving profitability and undervalued metrics support a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
